Baird lifts target for Cencora stock to USD 373.00
Published on 10/16/2026 at 16:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBaird target and results date
- Baird lifted its Cencora target to USD 373.00 on October 12, 2026.
- Fiscal third-quarter revenue reached USD 84.75 billion for the period ended June 30, 2026.
- Cencora stock costs EUR 303.25 at Lang & Schwarz on October 16, 2026 at 4:07 p.m. CEST.
- Cencora plans to publish fiscal fourth-quarter results on November 4, 2026.
Baird lifted its price target for Cencora from USD 370.00 to USD 373.00 on October 12, 2026, according to Yahoo Finance. The new target stood 9.44 percent above Cencora's USD 340.84 NYSE price at 10:19 a.m. ET on October 16, 2026. Cencora stock was trading at EUR 303.25 at Lang & Schwarz on October 16, 2026 at 4:07 p.m. CEST.
Revenue reaches USD 84.75 billion
Cencora reported fiscal third-quarter revenue of USD 84.75 billion for the period ended June 30, 2026, up 5.10 percent from USD 80.66 billion a year earlier, according to Ticker Scout. Net income attributable to Cencora reached USD 763.52 million, while GAAP diluted earnings per share came to USD 3.94, compared with USD 3.52 in the year-earlier quarter. The report also showed gross profit of USD 3.61 billion, up 24.10 percent year over year.
Price sits below its yearly high
The NYSE price of USD 340.84 was 9.72 percent below the 52-week high of USD 377.54 and stood above the 52-week low of USD 244.82 on October 16, 2026. The latest U.S. quote was below its yearly peak, while Cencora's euro quotation remained above EUR 300.00 in late trading in Germany.
Valuation and November results
Cencora's market capitalization was USD 65.0 billion and its trailing price-to-earnings ratio was 25.28 on October 16, 2026. The company plans to release fiscal fourth-quarter results before the NYSE open on November 4, 2026, and will hold its earnings call at 8:30 a.m. ET, according to Cencora.
Comparison with peers
Cencora Inc. (NYSE, USD): P/E 25.28, market capitalization USD 65.0 billion
McKesson Corporation (NYSE, USD): plus 0.18 percent, P/E 26.79, market capitalization USD 116.6 billion
Cardinal Health, Inc. (NYSE, USD): plus 0.04 percent, P/E 35.10, market capitalization USD 58.8 billion
The euro quote
Cencora's current valuation sits between the market capitalizations of McKesson and Cardinal Health, while its P/E ratio is below Cardinal Health's and close to McKesson's. The next scheduled company date is November 4, 2026, when Cencora plans to publish its fiscal fourth-quarter figures.
Cencora was trading at EUR 303.25 at Lang & Schwarz on October 16, 2026 at 4:07 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Cencora stock.
Cencora stock at a glance
- Company: Cencora, Inc.
- ISIN: US03073E1055
- Ticker: COR
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 16, 2026, 4:07 p.m. CEST): EUR 303.25
- Market capitalization: USD 65.0 billion (as of October 16, 2026)
- 52-week range: USD 244.82-377.54 (as of October 16, 2026)
- Sector / Industry: Healthcare / Medical Distribution
- Index membership: S&P 500
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
